Skip to main content
Clinical Trials/NCT06033378
NCT06033378
Recruiting
Not Applicable

Blood Pressure Treatment in ICU Patients with Subarachniodal Haemorrhage. -Can Blood Pressure Be Used As a Surrogate Marker for Blood Flow

Umeå University1 site in 1 country30 target enrollmentSeptember 1, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Blood Pressure
Sponsor
Umeå University
Enrollment
30
Locations
1
Primary Endpoint
Cerebral blood flow
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

An MRI study to examine the relationship between blood pressure and cerebral blood flow in patients with subarachnoidal hemorrhage and suspect or verified vasospasm.

Detailed Description

Subarachnoidal hemorrhage (SAH) is a type of stroke with high mortality rates and often requires care at the intensive care unit. Cerebral blood flow (CBF) needs to be ensured so that the brain receives optimal nourishment, and this is largely controlled by regulating blood pressure (BP) using medications that affect the heart and blood vessels. Approximately 3-7 days after SAH onset, vasospasm (SAH-V) can occur. Treatment usually includes maintaining blood pressure (BP) above a certain threshold to achieve adequate cerebral blood flow (CBF). An important component of raising BP is increasing vascular resistance using vasoconstrictive medications, which paradoxically can decrease CBF. The study objective is to investigate the correlation between BP changes and their impact on CBF in patients with suspect or verified SAH-V using MRI. To achieve this purpose, the investigators plan to examine the relationship between BP and CBF in patients with SAH-V who require neuro-intensive care. To measure CBF, two techniquis will be used: phase-contrast MRI and arterial spin labeling. Flow measurement with MRI: 1. Baseline images will be acquired at baseline blood pressure. 2. Mean arterial pressure (MAP) will be increased using norepinephrine. New images will be acquired when MAP is increased by approximately 20-30% from the baseline. All BP levels will be maintained within clinically acceptable ranges. All data will be recorded in the patient's medical record, and MRI images will be processed at a later stage.

Registry
clinicaltrials.gov
Start Date
September 1, 2023
End Date
September 1, 2028
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Coiled or clipped aneurysm
  • Suspected or confirmed vasospasm

Exclusion Criteria

  • Pregnancy
  • Pacemaker or other MRI contraindications
  • Severe congestive heart failure (NYHA III-IV) or cardiac arrhythmia.
  • Severe respiratory failure or FiO2 \>0.6
  • Severe kidney failure

Outcomes

Primary Outcomes

Cerebral blood flow

Time Frame: 1 hour

mL/min as measured by MRI

Study Sites (1)

Loading locations...

Similar Trials